Alex Schwarz, PhD, serves as Vice President, CMC, of Retinagenix Therapeutics Inc. He received his PhD in Bioengineering from the University of Bonn, Germany. Following a post-doc at the Weizmann Institute, he started his industrial career in protein separation of monoclonal antibodies. He has been engaged in the pharmaceutical and medical device industry for many years, developing for example long-acting drug delivery systems and medical devices such as glues and embolics. He has worked for small (Biosphere Medical, Aeris Therapeutics, Braeburn) and large companies (Baxter, Endo Pharmaceuticals, Novartis). He founded Pluromed, Inc. (sold to Sanofi) developing novel polymer systems for bypass surgery. Prior to joining Retinagenix he served as VP, Formulation, for Eyenovia, Inc., an innovative Ophthalmic company, where he provided scientific leadership in formulation development and GMP manufacturing. He is an inventor on 29 issued US patents and many international patents as well over 40 peer-reviewed publications.